avanti polar lipids/3D-PHAD®/1mg/699852P-1mg,avanti polar lipids,,Avanti Polar,Avanti,avantilipids,Avanti Polar Lipids Inc,中国Avanti Polar公司 Avanti Polar Lipids脂质体挤出器,,Array.Array.Array蚂蚁淘厂家直采.

产品名称：avanti polar lipids/3D-PHAD®/1mg/699852P-1mg

产品编号：699852P-1mg

市场价：¥4933.80

场地：美国(厂家直采)

产品分类：生化试剂>其他>酯>

联系QQ：1570468124

电话号码：4000-520-616

邮箱： info@ebiomall.com

美元价：$246.69

品牌： avanti polar lipids

公司：Avanti Lipids Polar, Inc.

公司分类：

商品介绍

699852 | 3D-PHAD®

Monophosphoryl 3-Deacyl Lipid A (Synthetic)Pat No. 9,241,988

Info

3D-PHAD®

Monophosphoryl 3-Deacyl Lipid A (Synthetic)Pat No. 9,241,988

Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD®), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

The highly pure MPLA analog, 3D-PHAD®, provides a homogeneous synthetic equivalent for the 3-deacylated MPLA derived from bacterial LPS. While comparable to bacterial MPLA and other synthetic MPLA analogs at eliciting an immune response in a liposomal adjuvant system (see bar graph), 3D-PHAD® is less pyrogenic than its bacterial-derived mimic. Extensive preclinical testing with 3D-PHAD® demonstrated equivalency to PHAD®, and human trials have been scheduled for launch. 3D-PHAD® is protected under Pat No. 9,241,988. Licensing opportunities are available for vaccine or immunotherapy commercialization.

Stimulatory effect of PHAD®, 3D-PHAD®, and 3D(6-acyl)-PHAD® on macrophages. Macrophage cell line J774 cells were cultured with Avanti PHAD®, 3D-PHAD®, or 3D(6-acyl)-PHAD® for 24hrs. IL-12 levels in supernatants were measured by sandwich ELISA.

Adjuvant Activity

PHAD®, 3D-PHAD®, and 3D(6A)-PHAD® have been tested extensively in animals using a variety of antigens. In all cases, these adjuvants exhibit a similar activity and safety profile to bacterially-derived MPL. The data above demonstrate the equivalency of the three synthetic adjuvants to the bacterially-derived MPL when presented in a liposomal carrier system (DMPC/DMPG/Cholesterol).

Data

Hygroscopic

Light Sensitive

Molecular Formula

C₈₂H₁₅₈N₃O₂₀P

Percent Composition

C 64.07%, H 10.36%, N 2.73%, O 20.82%, P 2.02%

Purity

>99%

Stability

1 Years

Storage Temperature

-20°C

CAS Number

1699735-79-9 CAS Registry Number is a Registered Trademark of the American Chemical Society

FormulaWeight

1537.114

Exact Mass

1536.118

Downloads

ChemDraw File
3D Structure
Structure
Brochure
699852 Adjuvant Data
Safety Data Sheet

References

Singh P, Matyas GR, Anderson A, Beck Z. Biophysical characterization of polydisperse liposomal adjuvant formulations. Biochem Biophys Res Commun. 2020 Aug 20;529(2):362-365. doi: 10.1016/j.bbrc.2020.05.156. Epub 2020 Jul 1. PMID: 32703436.

PubMed ID: 32703436

Martin ML, Bitzer AA, Schrader A, Bergmann-Leitner ES, Soto K, Zou X, Beck Z, Matyas GR, Dutta S. Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin. Malar J. 2019 Nov 27;18(1):377. doi: 10.1186/s12936-019-3014-5.

PubMed ID: 31775762

Hernandez A, Luan L, Stothers CL, Patil NK, Fults JB, Fensterheim BA, Guo Y, Wang J, Sherwood ER, Bohannon JK. Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens. Crit Care Med. 2019 Nov;47(11):e930-e938. doi: 10.1097/CCM.0000000000003967.

PubMed ID: 31567352

Beugeling M, De Zee J, Woerdenbag HJ, Frijlink HW, Wilschut JC, Hinrichs WLJ. Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly. Expert Rev Vaccines. 2019 Sep;18(9):935-950. doi: 10.1080/14760584.2019.1657013. Epub 2019 Aug 25.

PubMed ID: 31446807

Singh P, Bodycomb J, Travers B, Tatarkiewicz K, Travers S, Matyas GR, Beck Z. Particle size analyses of polydisperse liposome formulations with a novel multispectral advanced nanoparticle tracking technology. Int J Pharm. 2019 Jul 20;566:680-686. doi: 10.1016/j.ijpharm.2019.06.013. Epub 2019 Jun 6.

PubMed ID: 31176851

Smith RJ, Bryant RG. Metal substitutions incarbonic anhydrase: a halide ion probe study. Biochem Biophys Res Commun. 1975 Oct 27;66(4):1281-6.

PubMed ID: 31043512

Cawlfield A, Genito CJ, Beck Z, Bergmann-Leitner ES, Bitzer AA, Soto K, Zou X, Hadiwidjojo SH, Gerbasi RV, Mullins AB, Noe A, Waters NC, Alving CR, Matyas GR, Dutta S. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ). Vaccine. 2019 Jun 27;37(29):3793-3803. doi: 10.1016/j.vaccine.2019.05.059. Epub 2019 May 28.

PubMed ID: 31151801

Taleghani N, Bozorg A, Azimi A, Zamani H. Immunogenicity of HPV and HBV vaccines: adjuvanticity of synthetic analogs of monophosphoryl lipid A combined with aluminum hydroxide. APMIS. 2019 Mar;127(3):150-157. doi: 10.1111/apm.12927.

PubMed ID: 30746792

Certificates of Analysis

Certificate of Analysis(Lot No. 699852P-1MG-A-012and 5089PGA012)
Certificate of Analysis(Lot No. 699852P-5MG-A-012and 5089PHA012)
Certificate of Analysis(Lot No. 699852P-1MG-B-012and 5089PGB012)
Certificate of Analysis(Lot No. 699852P-5MG-B-012and 5089PHB012)
Certificate of Analysis(Lot No. 699852P-1MG-B-013and 5089PGB013)
Certificate of Analysis(Lot No. 699852P-5MG-A-013and 5089PHA013)
Certificate of Analysis(Lot No. 699852P-1MG-C-013and 5089PGC013)
Certificate of Analysis(Lot No. 699852P-1MG-D-013and 5089PGD013)
Certificate of Analysis(Lot No. 699852P-5MG-B-013and 5089PHB013)
Certificate of Analysis(Lot No. 699852P-5MG-C-013and 5089PHC013)
Certificate of Analysis(Lot No. 699852P-1MG-E-013and 5089PGE013)
Certificate of Analysis(Lot No. 699852P-5MG-G-013and 5089PHG013)
Certificate of Analysis(Lot No. 699852P-5MG-I-013and 5089PHI013)
Certificate of Analysis(Lot No. 699852P-5MG-H-013and 5089PHH013)

Base Price:${originalprice|money}

Custom Packaging:(${concentration} @$4.00/ea. + $100)${custompackagingtotal|money}

Packaging:${concentration}

Item Total:${totalprice|money}

(Sales Tax may apply)

Please select an option above.

Selected Product${sku} - ${concentration}

品牌介绍

Avanti Polar Lipids.jpg

Avanti Polar Lipids公司是美国著名的磷脂类产品的生产商，该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。为世界范围内的研究机构和制药公司提供 1000 种以上脂类产品，由于其产品的高纯度而享誉全球。40年来，Avanti Polar Lipids公司为世界各地的研究人员和制药公司提供脂类产品。公司的产品不仅范围日益扩大，其纯度之高也是无人能及。

Avanti Polar Lipids, Inc., has a long history of 50 years creating the highest purity lipids available. Our passion for high quality and unique products is only exceeded by our excellent reputation in the marketplace. Although we are known for our lipids, we are More than Lipids. We offer solutions for the entire product cycle…Research to Commercialization.

Avanti Polar Lipids公司的主要产品和服务包括：

（1）Research Products

Highest Purity Lipid Reagents

（2）cGMP Manufacturing

API & Contract Manufacturing

（3）Adjuvants

Immunotherapy & Vaccine Development

（4）Analytical Services

Lipid Analysis

（5）Lipidomics

Mass Spec Standards, Antibodies & Lipid Toolbox

（6）Formulations